DK2747763T3 - (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser - Google Patents

(bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser Download PDF

Info

Publication number
DK2747763T3
DK2747763T3 DK12762405.4T DK12762405T DK2747763T3 DK 2747763 T3 DK2747763 T3 DK 2747763T3 DK 12762405 T DK12762405 T DK 12762405T DK 2747763 T3 DK2747763 T3 DK 2747763T3
Authority
DK
Denmark
Prior art keywords
photosensibilizers
bacterio
chlorophyll
disorders
treatment
Prior art date
Application number
DK12762405.4T
Other languages
Danish (da)
English (en)
Inventor
Avigdor Scherz
Yoram Salomon
Arie Marcovich
Alexander Brandis
Daniel Wagner
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK2747763T3 publication Critical patent/DK2747763T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12762405.4T 2011-08-23 2012-08-23 (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser DK2747763T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526414P 2011-08-23 2011-08-23
PCT/IL2012/050325 WO2013027222A1 (en) 2011-08-23 2012-08-23 (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders

Publications (1)

Publication Number Publication Date
DK2747763T3 true DK2747763T3 (da) 2021-03-29

Family

ID=46889394

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12762405.4T DK2747763T3 (da) 2011-08-23 2012-08-23 (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser

Country Status (20)

Country Link
US (4) US9452172B2 (enExample)
EP (1) EP2747763B1 (enExample)
JP (1) JP6215203B2 (enExample)
KR (1) KR101962991B1 (enExample)
CN (1) CN103930108B (enExample)
AU (1) AU2012298156B2 (enExample)
BR (1) BR112014004306A2 (enExample)
CA (1) CA2846011C (enExample)
CL (1) CL2014000432A1 (enExample)
DK (1) DK2747763T3 (enExample)
ES (1) ES2856698T3 (enExample)
HK (1) HK1199412A1 (enExample)
HU (1) HUE053321T2 (enExample)
IN (1) IN2014CN02153A (enExample)
MX (1) MX360683B (enExample)
PE (1) PE20141183A1 (enExample)
PT (1) PT2747763T (enExample)
RU (1) RU2632439C2 (enExample)
WO (1) WO2013027222A1 (enExample)
ZA (1) ZA201402056B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP4420725A3 (en) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
WO2017015471A1 (en) 2015-07-21 2017-01-26 Avedro, Inc. Systems and methods for treaments of an eye with a photosensitizer
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
CN105601638B (zh) * 2016-01-28 2018-10-26 东北林业大学 一种叶绿酸衍生物及其制备方法、作为光敏抑菌剂及光敏杀虫剂的应用
US10342697B2 (en) 2016-04-13 2019-07-09 Avedro, Inc. Systems and methods for delivering drugs to an eye
EP4335419A3 (en) * 2016-05-05 2024-04-03 David Muller Corneal implant systems and methods
US10849855B2 (en) * 2017-01-03 2020-12-01 Vitrean, Inc. Methods and devices for treating a retinal detachment
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
CN109091685A (zh) * 2018-08-10 2018-12-28 北京市眼科研究所 一种对角膜炎提取细菌病原体的灭活方法
KR20210093901A (ko) * 2018-10-24 2021-07-28 캘리포니아 인스티튜트 오브 테크놀로지 일중항 산소를 사용한 근시 및 기타 안구 질환의 치료
US11702546B2 (en) 2018-10-24 2023-07-18 California Institute Of Technology Near-infrared heptamethine dyes for generation of singlet oxygen
WO2020117974A1 (en) * 2018-12-04 2020-06-11 Avedro, Inc. Compounds and compositions for eye treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102645A (en) 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
RU2201219C2 (ru) * 2001-04-24 2003-03-27 Макаров Константин Алексеевич Фармакологическая композиция пролонгированного действия
US20040266748A1 (en) * 2001-10-03 2004-12-30 Robinson Byron C Photosensitizing carbamate derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
EP1753457B8 (en) * 2004-06-07 2016-09-21 Yeda Research And Development Co., Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
KR101502632B1 (ko) 2006-10-24 2015-03-17 캘리포니아 인스티튜트 오브 테크놀로지 신체 조직의 물리적 및/또는 화학적 성질에 영향을 주는 광화학적 요법
RU2404768C1 (ru) * 2009-10-28 2010-11-27 Федеральное агентство по науке и инновациям Глазные капли
JPWO2011099602A1 (ja) * 2010-02-12 2013-06-17 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用

Also Published As

Publication number Publication date
ZA201402056B (en) 2015-11-25
BR112014004306A2 (pt) 2017-03-28
JP6215203B2 (ja) 2017-10-18
US20190231874A1 (en) 2019-08-01
US20140378888A1 (en) 2014-12-25
CN103930108B (zh) 2017-05-24
CL2014000432A1 (es) 2014-11-28
RU2632439C2 (ru) 2017-10-04
MX2014002107A (es) 2015-04-16
US20160354468A1 (en) 2016-12-08
AU2012298156A1 (en) 2014-04-10
EP2747763B1 (en) 2020-12-30
HUE053321T2 (hu) 2021-06-28
PT2747763T (pt) 2021-02-22
IN2014CN02153A (enExample) 2015-05-29
KR20140088514A (ko) 2014-07-10
CN103930108A (zh) 2014-07-16
US9452172B2 (en) 2016-09-27
ES2856698T3 (es) 2021-09-28
MX360683B (es) 2018-11-13
HK1199412A1 (en) 2015-07-03
JP2014524465A (ja) 2014-09-22
WO2013027222A1 (en) 2013-02-28
US11058772B2 (en) 2021-07-13
KR101962991B1 (ko) 2019-03-27
EP2747763A1 (en) 2014-07-02
CA2846011A1 (en) 2013-02-28
CA2846011C (en) 2019-10-15
US20210330792A1 (en) 2021-10-28
AU2012298156B2 (en) 2017-08-17
PE20141183A1 (es) 2014-10-05
RU2014110784A (ru) 2015-09-27

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
IL260585B (en) Compositions and methods for treating retinal diseases
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK2877184T3 (da) Sammensætninger og behandling for øjensygdomme og -lidelser
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
DK2830662T3 (da) Fremgangsmåder til behandlng af hårtabsforstyrrelser
IL231533A0 (en) Fusion proteins for treating metabolic disorders
EP3473216C0 (en) DEVICE FOR TREATING AN EYE DISORDER
IL238432A0 (en) Methods and devices for the treatment of ocular diseases in human subjects
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
IL229017B (en) Oxidative retinal diseases
CO6811859A2 (es) Método de tratamiento de los trastornos de la visión
IL232710B (en) L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
LT3292875T (lt) Kompozicijos ir būdai, skirti ligų gydymui
IL233639B (en) Compositions and methods for the treatment of hepatic diseases and disorders
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
BR112014004306A2 (pt) fotossensibilizadores de (bacterio)clorofila para tratamento de doenças e distúrbios do olho
DK2522342T3 (da) Topisk formulering til behandling af hyperkeratonisk hud
DK2961426T3 (da) Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g
HUE040231T2 (hu) Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
IL234606B (en) Novel methods and composition for treatment of disease
DK2673363T3 (da) Behandling af angiogenesesygdomme